Rodman & Renshaw started coverage on shares of CytoDyn Inc. (OTCMKTS:CYDY) in a research report released on Thursday. The firm issued a buy rating and a $1.60 target price on the biotechnology company’s stock.

CytoDyn (OTCMKTS:CYDY) opened at 0.695 on Thursday. The company has a 50-day moving average of $0.85 and a 200 day moving average of $1.04. The company’s market cap is $86.55 million. CytoDyn has a 52-week low of $0.63 and a 52-week high of $1.57.

CytoDyn Company Profile

CytoDyn Inc is a biotechnology company focused on discovering and developing a class of therapeutic monoclonal antibodies to treats Human Immunodeficiency Virus (HIV) infection. Its lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors. These therapies potentially block HIV from entering into and infecting certain cells.

Receive News & Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related companies with's FREE daily email newsletter.